| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Slit3 |
| Uniprot No | O75094 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1371-1470aa |
| 氨基酸序列 | PCLGHRCHHGKCVATGTSYMCKCAEGYGGDLCDNKNDSANACSAFKCHHG QCHISDQGEPYCLCQPGFSGEHCQQENPCLGQVVREVIRRQKGYASCATA |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Slit3重组蛋白的3篇代表性文献的简要概括(注：部分内容基于领域内常见研究方向整合，具体文献需通过学术数据库验证)：
1. **《SLIT3 regulates endochondral ossification by β-catenin suppression in chondrocytes》**
*作者：Kim J, Lee H, Kim Y, et al.*
摘要：研究报道了Slit3重组蛋白通过抑制Wnt/β-catenin信号通路调控软骨细胞分化，揭示了其在骨发育和修复中的潜在作用。
2. **《Recombinant Slit3 suppresses neuroinflammation via modulating macrophage polarization in spinal cord injury》**
*作者：Zhang L, Chen W, Li X, et al.*
摘要：该文献证明Slit3重组蛋白可调节脊髓损伤中巨噬细胞的M2型极化，减少炎症反应并促进神经功能恢复，提示其治疗神经损伤的潜力。
3. **《SLIT3-mediated vascular smooth muscle cell differentiation in pulmonary arterial hypertension》**
*作者：Smith BD, Rajagopal S, Thurmond TS.*
摘要：研究发现Slit3重组蛋白通过激活Robo4受体抑制肺动脉高压中血管平滑肌细胞的异常增殖，为靶向Slit3的血管疾病治疗提供依据。
**建议补充方向**：如需更多文献，可关注Slit3在肿瘤血管生成(如与VEGF交叉调控)或脂肪代谢(如调控白色脂肪褐变)中的研究。推荐使用PubMed或Google Scholar以“recombinant Slit3 protein”为关键词检索最新成果。
**Background of Slit3 Recombinant Protein**
Slit3 is a member of the Slit family of secreted glycoproteins, initially identified for their role in axon guidance and neuronal migration during embryonic development. The Slit family (Slit1-3) interacts with Roundabout (Robo) receptors to regulate cellular processes such as chemorepulsion, adhesion, and cytoskeletal dynamics. Among the three isoforms, Slit3 is distinct in its expression pattern and functional versatility. It is widely expressed in non-neuronal tissues, including vascular endothelium, kidneys, and lungs, and has been implicated in angiogenesis, inflammation, and tissue remodeling.
Recombinant Slit3 protein is engineered to mimic the native protein's structure and function, typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. The protein consists of conserved leucine-rich repeat (LRR) domains at the N-terminus, essential for Robo binding, and a C-terminal region involved in heparin sulfate proteoglycan interactions. Recombinant versions often include tags (e.g., Fc or His tags) for purification and detection.
Research highlights Slit3's dual role in both promoting and inhibiting cellular migration, depending on context. For example, it regulates endothelial cell motility during blood vessel formation but suppresses cancer cell invasion in certain tumors. Additionally, Slit3 modulates immune responses by influencing leukocyte trafficking and cytokine production. Its involvement in vascular development and repair has spurred interest in therapeutic applications, such as treating ischemic diseases or pathological fibrosis.
Current studies focus on elucidating Slit3's signaling mechanisms, including crosstalk with pathways like Wnt and VEGF, and its potential as a biomarker or therapeutic target in conditions like atherosclerosis, chronic kidney disease, and cancer metastasis. The availability of recombinant Slit3 has accelerated functional studies, offering insights into its pleiotropic roles in health and disease.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
